Plus   Neg

Immunogen Inc. (IMGN) Is Up Sharply On Study Results

Immunogen Inc. (IMGN) announced Friday morning that Roche has announced positive results from its trastuzumab emtansine EMILIA Phase III trial. Trastuzumab emtansine consists of ImmunoGen's cancer-killing agent, DM1, attached to the HER2-targeting antibody, trastuzumab, and is in global development by Roche under an agreement between ImmunoGen and Genentech.

Immunogen has gapped open sharply higher Friday and is now up 1.76 at $15.50 on above average volume. The stock is now challenging the highs of the year, trading at an 8-month high.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Trade IMGN now with 
Follow RTT